Page 10 of 19: studies 91 to 100 of 190, newest first. Back to the MDMA for PTSD overview
Mental Health Weekly September 25, 2023 Valerie A. Canady
The third part of a new study assessing MDMA‐assisted therapy, a psychedelic drug also known as Ecstasy, has revealed improvement in diverse individuals suffering with severe post‐traumatic stress disorder (PTSD). The study, “MDMA‐assisted therapy for moderate to severe PTSD: a randomized, placebo‐controlled phase 3 trial,” published Sept. 14 in Nature Medicine.
Psychiatric News September 22, 2023
Back to table of contents Previous article Next article Clinical & ResearchFull AccessMDMA-Assisted Therapy for PTSD Shows Promise for Patients of Diverse BackgroundsSearch for more papers by this authorPublished Online:22 Sep 2023https://doi.org/10.1176/appi.pn.2023.10.10.60AbstractMDMA appears to enhance the ability of individuals with PTSD to benefit from psychotherapy by softening their...
Current Problems of Psychiatry September 22, 2023 Wiktoria Bojarska, Karolina Bury, Radosław Januszczak et al.
Introduction: Post-traumatic Stress Disorder (PTSD) is a mental illness caused by exposure to a traumatic event. The current treatment includes trauma-focused psychotherapy along with selective serotonin reuptake inhibitors (SSRI). It is estimated that for about 40-60% of patients it does not bring the desired improvement, which prompted scientists to look for new methods of pharmacotherapy....
Journal of Education Health and Sport August 15, 2023 Karol Womperski, Rafał Bogacz, Magdalena Gaik et al. 1 citation
Introduction: Post-traumatic stress disorder (PTSD) is a common health issue of complex etiology significantly deteriorating functioning in everyday life. It may develop as a result of exposure to traumatic events like traffic accidents, war experience, sexual abuse and domestic violence. Current methods of treatment consist of trauma-oriented psychotherapy supported by selective serotonin...
Nature July 13, 2023 Rich Haridy 55 citations
Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed. Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed.
British medical journal July 11, 2023 B. Nogrady 18 citations
The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...
Focus July 1, 2023 Benjamin R. Lewis, Kevin Byrne 9 citations
Posttraumatic stress disorder (PTSD) is a common chronic and disabling psychiatric disorder that may develop after exposure to a traumatic life event. There are existing evidence-based psychotherapies and pharmacotherapies for PTSD; however, these treatments have significant limitations. 3,4-methylenedioxymethamphetamine (MDMA) was granted "breakthrough therapy" status by the U.S. Food and Drug...
Focus (American Psychiatric Publishing) July 1, 2023 Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. 97 citations
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...
Frontiers in Psychiatry April 14, 2023 Jennifer L. Jones 4 citations
BackgroundAlcohol and other substance use disorders are commonly associated with post-traumatic stress disorder (PTSD), and the presence of these comorbidities is associated with worse treatment outcomes. Additionally, disparities in substance and PTSD prevalence have been associated with minority races and ethnicities, and minorities have been shown to be less likely to engage in treatment....
The Australian and New Zealand journal of psychiatry April 1, 2023 Gillinder Bedi, Susan M Cotton, Alexandre A. Guerin et al. 17 citations
Recent years have seen escalating media, public and scientific interest in psychedelic medicine. Australia and New Zealand have been late to this research; however, in the past 2 years, rapid developments suggest that this is changing. Here, we argue for the need to critically review existing evidence in this field to guide future directions. We focus on...